Xbrane Biopharma AB
F:7XB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.3625
3.75
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Xbrane Biopharma AB
Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. The company is headquartered in Solna, Stockholm. The company went IPO on 2016-02-03. The company develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The firm's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
Xbrane Biopharma AB is a biopharmaceutical company, which engages in the development and manufacture of biosimilars. The company is headquartered in Solna, Stockholm. The company went IPO on 2016-02-03. The company develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The firm's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
